C. M. Zwaan

发表

Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression

K. Juul-Dam, Milad Rasouli, Branko Cuglievan, 2023, European journal of medical genetics.

Repurposing CD19-directed immunotherapies for pediatric t(8;21) acute myeloid leukemia

Annelisa M Cornel, F. Barneh, G. Kaspers, 2024, bioRxiv.

Precision cancer medicine platform trials: Concepts and design of AcSé-ESMART.

A. Marchais, S. Gatz, K. Nysom, 2024, European journal of cancer.

Evolution of the Innovative Therapies for Children With Cancer Consortium Trial Portfolio for Drug Development for Children With Cancer.

L. Marshall, A. Rubio-San-Simón, Francisco Bautista, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting the innate immune system in pediatric and adult AML

J. Koedijk, A. Perzolli, Olaf Heidenreich, 2024, Leukemia.

Selective pressures of platinum compounds shape the evolution of therapy-related myeloid neoplasms

R. van Boxtel, M. V. D. van den Heuvel-Eibrink, M. Verheul, 2024, Nature communications.

Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059

U. Dirksen, C. Rossig, B. Bielorai, 2024, Clinical pharmacokinetics.

Distinct Responses to Menin Inhibition and Synergy with DOT1L Inhibition in KMT2A-Rearranged Acute Lymphoblastic and Myeloid Leukemia

R. Stam, A. Zakharenko, J. Stutterheim, 2024, International journal of molecular sciences.

Integrated drug resistance and leukemic stemness gene-expression scores predict outcomes in large cohort of over 3500 AML patients from 10 trials

S. Meshinchi, T. Alonzo, J. Rubnitz, 2024, npj Precision Oncology.

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study

J. Dipersio, N. Shukla, E. Traer, 2023, Blood.

The PedAL/EuPAL Project: A Global Initiative to Address the Unmet Medical Needs of Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia

G. Kaspers, S. Tasian, S. Ishimaru, 2023, Cancers.

Case Report: Immune dysregulation associated with long-lasting regression of a (pre)leukemic clone

J. Koedijk, Elizabeth K. Schweighart, M. Vermeulen, 2023, Frontiers in immunology.

Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia

Erica Brivio, C. M. Zwaan, Francisco Bautista, 2024, Haematologica.

Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial

K. McHugh, N. Fenwick, G. Barone, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NUP98 oncofusions in myeloid malignancies: An update on molecular mechanisms and therapeutic opportunities

Milad Rasouli, Selina Troester, Olaf Heidenreich, 2024, HemaSphere.